KPV
A tripeptide derived from the tail end of the hormone alpha-MSH, studied for anti-inflammatory effects, particularly in the gut and skin. The research is mostly preclinical, with little human trial data to confirm popular uses.
Quick take
- What it is: a three–amino-acid peptide (lysine-proline-valine) that is the active C-terminal fragment of the hormone alpha-MSH.
- What people use it for: calming inflammation, especially in the gut and skin.
- What we actually know: it shows anti-inflammatory activity in cell and animal studies; human clinical evidence is very limited.
- Status: not FDA-approved; sold only as an unapproved research peptide.
What it is
KPV is a tripeptide — a chain of just three amino acids, lysine, proline and valine — that corresponds to the final three residues at the tail (C-terminus) of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signalling hormone.1 This short fragment is of interest because it appears to keep alpha-MSH’s anti-inflammatory activity while shedding the pigment- and appetite-related effects of the full molecule.
It is promoted mainly as an anti-inflammatory peptide, often for gut and skin issues. As always, that popularity should be weighed against the actual evidence, covered below.
How it works
In laboratory studies, KPV appears to dampen inflammatory signalling inside cells — for example by interfering with pathways such as NF-κB that drive the production of inflammatory molecules.2 Some research suggests it can be taken up directly by cells of the gut lining, which is part of the rationale for studying it in intestinal inflammation.
These mechanisms are plausible and reasonably consistent in the lab, but how fully they translate into clinical benefit in people is not established.
What the evidence shows
Laboratory and animal studies
Most KPV research is preclinical. In cell cultures and in animal models of colitis and intestinal inflammation, KPV has been reported to reduce inflammatory markers and improve measures of gut inflammation.2,3 Related work has explored anti-inflammatory effects in skin. This body of model evidence is what underpins its reputation.
Human studies
Published, peer-reviewed human clinical trials for KPV’s popular uses are essentially absent. Reports of benefit in people are largely anecdotal. The key takeaway is encouraging anti-inflammatory activity in models, but unproven in humans.
Dosages reported in the literature
Informational only. The figures below describe doses reported in research and anecdotal use. They are not a recommendation or a prescription. Appropriate use, if any, should be determined by a qualified healthcare professional who can account for your individual situation.
| Setting | Route | Reported range |
|---|---|---|
| Animal / lab research | Injection / oral | Varies widely; not directly applicable to humans |
| Anecdotal / clinic-reported | Oral or subcutaneous | Reported in low microgram-to-milligram amounts daily |
Because there are no dose-finding human trials, no range here should be read as established as safe or effective. Reported protocols vary widely between sources.
Safety & side effects
There are no long-term controlled human safety data for KPV. The limited reports describe it as generally well tolerated, but this rests on anecdote and preclinical work rather than rigorous human monitoring.
As with other unregulated peptides, product identity, purity and dose accuracy can vary considerably between sources — a key reason professional sourcing and clinician oversight matter for anyone considering its use.
Legal & regulatory status
KPV is not approved by the FDA for any use, and it is not an approved medicine in the United States or most other countries. It is sold only as an unapproved research peptide.4 Rules differ by country and change over time.
References
- Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews. 2004;56(1):1-29. [PMID 15001661, doi:10.1124/pr.56.1.1]
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. [PMID 18061177, doi:10.1053/j.gastro.2007.10.026]
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. [PMID 18092346, doi:10.1002/ibd.20334]
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). FDA; January 2025. [fda.gov]